## 3 Results
\begin{table}
\begin{tabular}{c c c c c c} \hline \hline  & **\textless{}300 Eosinophils** & **\textgreater{}300 Eosinophils** & **\(p\)** & RR & OR \\ \hline Simple size & 455 & 108 & - & - & - \\ \hline Age & 43.63 \(\pm\) 14.79 & 38.99 \(\pm\) 14.17 & 0.003 & - & - \\ \hline Men & 131 (29\%) & 45 (42\%) & 0.009 & 0.530 & 1.767 \\ \hline Women & 324 (71\%) & 63 (58\%) & 0.009 & 1.221 & 1.767 \\ \hline BMI & 26.97 \(\pm\) 5.60 & 26.74 \(\pm\) 5.22 & - & - & - \\ \hline FEV 1 Volume & 3.12 \(\pm\) 0.85 & 3.26 \(\pm\) 0.84 & - & - & - \\ \hline FEV 1\% & 104.97 \(\pm\) 13.83 & 103.15 \(\pm\) 13.28 & - & - & - \\ \hline FEV 1 Zscore & \(-\)0.49 \(\pm\) 1.40 & \(-\)0.26 \(\pm\) 1.62 & - & - & - \\ \hline FVC Volume & 3.83 \(\pm\) 1.02 & 4.02 \(\pm\) 0.98 & - & - & - \\ \hline FVC\% & 108.95 \(\pm\) 13.57 & 107.43 \(\pm\) 13.04 & - & - & - \\ \hline FVC Szscore & \(-\)0.52 \(\pm\) 1.47 & \(-\)0.17 \(\pm\) 1.55 & 0.034 & - & - \\ \hline FEV 1/FVC & 81.42 \(\pm\) 6.22 & 81.42 \(\pm\) 6.37 & - & - & - \\ \hline FEV 1/FVC Szscore & \(-\)0.03 \(\pm\) 0.88 & \(-\)0.18 \(\pm\) 0.94 & - & - & - \\ \hline FEF 25–75 Volume & 3.21 \(\pm\) 1.12 & 3.36 \(\pm\) 1.11 & - & - & - \\ \hline FEF 25–75\% & 87.29 \(\pm\) 23.47 & 85.75 \(\pm\) 22.58 & - & - & - \\ \hline + Bronchodilation & 3 (1\%) & 0 (0\%) & - & - & - \\ \hline * Bronchodilation & 22 (7\%) & 4 (5\%) & - & - & - \\ \hline \(-\) Bronchodilation & 297 (92\%) & 76 (95\%) & - & - & - \\ \hline Asthma diagnosis & - & - & - & - & - \\ \hline Asthma onset prior to 12 years old & - & - & - & - & - \\ \hline Asthma onset prior to 40 years old & - & - & - & - & - \\ \hline Allergic asthma & - & - & - & - & - \\ \hline Asthma in symptomatic period & - & - & - & - & - \\ \hline Persistent asthma & - & - & - & - & - \\ \hline Current asthma symptoms & - & - & - & - & - \\ \hline Rhinitis & 353 (78\%) & 91 (84\%) & - & - & - \\ \hline Atopy & 304 (67\%) & 79 (73\%) & - & - & - \\ \hline Food allergy & 46 (10\%) & 9 (8\%) & - & - & - \\ \hline Drug allergy & 24 (5\%) & 10 (9\%) & - & - & - \\ \hline Contact dermatitis & 9 (2\%) & 1 (1\%) & - & - & - \\ \hline Other allergies & 9 (2\%) & 2 (2\%) & - & - & - \\ \hline FeNO & 22.60 (16.93) & 29.50 (38.18) & 0.001 & - & - \\ (ppb) & & & & & \\ \hline Eosinophil counts & 200 (100) & 500 (200) & 0.001 & - & - \\ (Eos/\(\mu\)L) & & & & & \\ \hline Total IgE & 92.90 (130.60) & 100. 99 (308.20) & - & - & - \\ (kU/L) & & & & & \\ \hline Comorbidities & 104 (23\%) & 27 (25\%) & - & - & - \\ \hline Atopic dermatitis & 7 (2\%) & 0 (0\%) & - & - & - \\ \hline \hline \end{tabular}
\end{table} 
Table 3: Clinical characteristics of non-asthmatics patients over 18 years old. Atopy still shows a higher prevalence and increased risk with higher eosinophil counts (150 \(p\) 0.007, RR 0.926, OR 0.480; 300 \(p\) 0.003, RR 0.930, OR 0.365) in low eosinophil count cut-off points, but these differences are minimised for higher thresholds such as 500 or 800 Eos/\(\upmu\)L. Contrarily, no differences exist when analysing rhinitis. Spirometric value changes were observed in the 300 (FEV1% \(p\) 0.001, FVC% \(p\) 0.039, FEV1/FVC \(p\) 0.001, FEV1/FVC Zscore \(p\) 0.001, FEF 25-75 \(p\) 0.007, FEF 25-75-% \(p\) 0.001), 500 (FEV1/FVC \(p\) 0.008, FEV1/FVC Zscore \(p\) 0.004, FEF 25-75% \(p\) 0.004) and 800 (FEV1/FVC \(p\) 0.017, FEV1/FVC Zscore \(p\) 0.012) cut-off points, but no statistically significant differences were spotted in the 150 Eos/\(\upmu\)L limit. When looking into patients without asthma, we can observe that the 150 Eos/\(\upmu\)L cut-off point led to differences in drug (probability value (_p_) 0.033, relative risk (RR) 0.408, odds ratio (OR) 0.389) and contact (_p_ 0.017, RR 4.438, OR 4.567) allergies. Moreover, rhinitis (_p_ 0.017, RR 0.894, OR 0.606) and atopy (_p_ 0.023, RR 0.408, OR 0.389) is more common among patients with more than 150 eosinophils, showing a higher risk of developing these conditions.